JUDY HARSSON: Open Payments
NPI 1477960995 · JONESBORO, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$498 in 25 payments from 10 companies in 2025. Trend: 2023 $144 · 2024 $240 · 2025 $498
Food & beverage: $498
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $204 |
| Sumitomo Pharma America, Inc. | 3 | $66 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $41 |
| Novo Nordisk Inc | 2 | $40 |
| Lundbeck LLC | 1 | $32 |
| Edwards Lifesciences Corporation | 1 | $31 |
| ABBVIE INC. | 1 | $24 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 2 | $21 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $15 |
Products named: AIRSUPRA, GEMTESA, FARXIGA, REXULTI, SAPIEN 3 Ultra RESILIA, Ozempic, LINZESS, CAPLYTA.
Industry payments across AR — which companies pay providers there.
